Lara Carmen Iglesias Docampo

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text

Medicine, Oncology, Metastasis +5

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · Oral Oncology · 2018 · 800 citations · Full text

Medicine, Oncology, Metastasis +14

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Maura L. Gillison, George R. Blumenschein, Jérôme Fayette et al. · The Oncologist · 2018 · 96 citations · Full text

Medicine, Oncology, Pharmacology +9

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

Maura L. Gillison, George R. Blumenschein, Jérôme Fayette et al. · The Oncologist · 2022 · 52 citations · Full text

Medicine, Oncology, Pharmacotherapy +13